Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

11/9/22 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CNCE alert in real time by email

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.

A webcast of the presentation may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay will be available on Concert's website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious autoimmune dermatological disease. The Company is also evaluating the use of deuruxolitinib in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit www.concertpharma.com or follow us on Twitter, Instagram or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005071/en/

Get the next $CNCE alert in real time by email

Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Chat with this insight

Recent Analyst Ratings for
$CNCE

$CNCE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G filed by Concert Pharmaceuticals Inc.

$CNCE
Leadership Updates

Live Leadership Updates

KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors

$CNCE
Financials

Live finance-specific insights

$CNCE
SEC Filings

$CNCE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$CNCE
Press Releases

Fastest customizable press release news feed in the world

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results

SEC Form 15-12G filed by Concert Pharmaceuticals Inc.

SEC Form EFFECT filed by Concert Pharmaceuticals Inc.

SEC Form EFFECT filed by Concert Pharmaceuticals Inc.

Mizuho reiterated coverage on Concert Pharmaceuticals with a new price target

Truist reiterated coverage on Concert Pharmaceuticals with a new price target

Truist Securities reiterated coverage on Concert Pharmaceuticals with a new price target

Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

$CNCE
Market Insights

Live Market Insights

Concert Pharmaceuticals Says FDA Determined That Deuruxolitinib Will Maintain Its Breakthrough Therapy Designation

JonesTrading Downgrades Concert Pharma to Hold

Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

$CNCE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Stuart Nancy sold $50,380 worth of shares (6,048 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 262,596 units (withholding obligation)

SEC Form 4: Munsie Jeffrey A sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 88,049 units to cover withholding tax

SEC Form 4: Cassella James V sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 173,061 units to satisfy withholding obligation

Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $CNCE

$CNCE Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G filed by Concert Pharmaceuticals Inc.

$CNCE Leadership Updates

Live Leadership Updates

KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors

$CNCE Financials

Live finance-specific insights

$CNCE SEC Filings

$CNCE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$CNCE Press Releases

Fastest customizable press release news feed in the world

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results

SEC Form 15-12G filed by Concert Pharmaceuticals Inc.

SEC Form EFFECT filed by Concert Pharmaceuticals Inc.

SEC Form EFFECT filed by Concert Pharmaceuticals Inc.

Mizuho reiterated coverage on Concert Pharmaceuticals with a new price target

Truist reiterated coverage on Concert Pharmaceuticals with a new price target

Truist Securities reiterated coverage on Concert Pharmaceuticals with a new price target

Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

$CNCE Market Insights

Live Market Insights

Concert Pharmaceuticals Says FDA Determined That Deuruxolitinib Will Maintain Its Breakthrough Therapy Designation

JonesTrading Downgrades Concert Pharma to Hold

Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

$CNCE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Stuart Nancy sold $50,380 worth of shares (6,048 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 262,596 units (withholding obligation)

SEC Form 4: Munsie Jeffrey A sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 88,049 units to cover withholding tax

SEC Form 4: Cassella James V sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 173,061 units to satisfy withholding obligation

Recent Analyst Ratings for
$CNCE

$CNCE
Large Ownership Changes

$CNCE
Leadership Updates

$CNCE
Financials

$CNCE
SEC Filings

$CNCE
Analyst Ratings

$CNCE
Press Releases

$CNCE
Market Insights

$CNCE
Insider Trading